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Abstract
∆9 -Tetrahydrocannabinol (THC) and cannabidiol (CBD) are phytocannabinoids that have a
potential impact in cancer treatments. Studies have shown that certain cannabinoids cause cancer
cells to die, but only with selective concentrations, which have not been well documented. The
first study of this thesis was to determine the exact concentration of CBD and THC needed to kill
human MCF-7 breast cancer cells, rather than creating mass multiplication leading to more
growth of the cancer. To conduct this experiment, cell culture was performed with a MCF-7
breast cancer cell line. The treatment groups were treated with CBD or THC at varying
concentrations including 0.1, 1, 10 and 100 µM. Observations were made by using tetrazolium
dye (MTT assay), which is a colorimetric assay for measuring cell proliferation. Additionally, as
an alternative approach to assess cell death, Western blot was performed. MCF-7 cells were
analyzed for apoptosis through Western blotting by detecting poly ADP ribose polymerase
(PARP) cleavage. CBD inhibited MCF-7 breast cancer growth, whereas THC stimulated MCF-7
breast cancer cell proliferation. MTT assay and Western blot displayed the same pattern with
CBD being the most effective treatment, but with different effective concentrations. The MTT
assay method suggested that 1 µM cannabidiol was the most effective, whereas the Western blot
indicated that 10 µM cannabidiol was the most effective. These results are inconstant and they
have not been replicated. This research is a continuation in which experiments will narrow the
effective concentration needed to cause cancer cells apoptosis. Favorable findings may provide
an accessible and affordable cannabinoid-based treatment for patients.
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The Effects of Cannabidiol and Tetrahydrocannabinol Concentration on Breast Cancer
Cells
One in eight women (about 12.5%) will develop invasive breast cancer over the course of
her lifetime (U.S Breast Cancer Statistics, 2018) in the United States. Not only is breast cancer
deadly, but breast cancer can spread to other parts of the body such as lymph nodes, lungs, and
other organs. Breast cancer cells in the lymph nodes suggest an increased risk of cancer
metastasis and decreased rate of survival. Breast cancer is treated in various ways such as
radiation and surgical removal of the breast, which leaves the survivors with physical and
emotional trauma. Chemotherapy is another common treatment but has side effects such as hair
lost, easy bruising, bleeding, and cognitive disorders which can affect concentration and focus
(American Cancer Society, 2016). Due to these negative side effects, researchers have been
looking for supportive alternate treatments that are equally effective but without the side effects.
One possibility: Cannabis-derived cannabinoid drugs. Cannabinoids are being investigated
(Qamri et al., 2009) as anticancer treatments with fewer side effects than conventional
chemotherapy.
Purpose and Significance
Studies suggest that cannabinoids can kill cancer cells, and researchers have proposed
that the concentration of cannabinoids makes a difference in determining cancer cell apoptosis
(cell death), however optimization of the cannabinoids concentration is necessary (Sarfaraz,
Adhami, Syned, Afaq, & Murkhtar, 2008). Sarfaraz et al. (2008) proposed that the
overexpression of cannabinoid receptors (CB1 and CB2: G-protein couple receptors located
throughout the body) may lead to cancer cell death, but little or no expression of these receptors
could lead to cell proliferation and metastasis due to the suppression of the antitumor immune
response. It is unknown how the concentrations of two common cannabinoids--cannabidiol
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(CBD) and ∆9 -tetrahydrocannabinol (THC) affect cancer cells. Therefore, studying the effect of
varying concentrations of CBD and THC on breast cancer cells could offer a potential avenue for
new treatments of this disease.
Because Cannabis is easily grown, the cost of cannabinoid-based cancer treatment could
potentially be much lower than other forms of chemotherapy (Gringsppoon, 1999). Furthermore,
cannabinoid drugs are known to reduce many side effects associated with other treatments, such
as pain, loss of appetite, nausea, and vomiting (Rocha, Stefano, Haiek, Oliveira & Da Silveria,
2008; Tramèr et al., 2001; Ware et al., 2010), which will benefit cancer patients by preventing
them from taking additional medications for side effects. The use of cannabinoid drugs can also
potentially void the need of traumatic surgeries. Lastly, when an effective concentration is
known for treatment, cannabinoids should work more efficiently than most other cancer
treatments because they inhibit the cancer growth without interfering with normal cells (Kogan,
2005). Not only are cannabinoid drugs affordable and have anti-proliferative properties, they can
reduce side effects associated with other treatments making cannabinoid drugs a potential
treatment to research and develop.
Review of Literature
Cancer Pathogenesis
During the cell cycle, there are checkpoints which are responsible for making sure the
cell is capable to function and regulate when necessary. At the checkpoint, if a cell has any
damage or cannot serve its purpose, the cell is marked for apoptosis. Apoptosis is a normal
physiological process which removes unwanted cells by programming the cell’s death. Some
damaged cells escape the checkpoint without being marked for apoptosis. These abnormal cells
can grow out of proportion and can become cancer cells (Visconti et al., 2016).
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Cancer cells are cells that have lost the ability to function normally or die but can still
divide. Uncontrollable growth forms a mass of tissue called a tumor. Because cancer cells are
similar to normal cells, it is difficult to selectively kill them without affecting normal cells
(Yasukawa, 2014). When the cancer cells spread to different regions of the body, it is called
metastasis. Cyclin E is a regulator of cell cycle and, with cyclin-dependent kinase (cdk) 2, is
important for the G1/S transition during the cell cycle. In tumors, there is normally an
overexpression of the cyclin E protein causing cell proliferation and bypassing the checkpoint
leading to cancer.
There are five types of cancer classified by their tissue/cell types of origin, which are
sarcomas, leukemia, lymphomas, melanoma, and carcinomas (Movva, 2015). Carcinomas, which
was the focus of this study, develop in the epithelial cells, which start from the skin or epithelial
tissue and spread to the internal organs and are caused by the damage of DNA resulting in a
mutation (Rosenbreg, 1987). MCF-7, which is a human breast adenocarcinoma cell line, was the
selected cell type utilized. Breast cancer is the most common cancer and the leading cause of
cancer death in American women. American Cancer Society estimated 41,400 deaths occurred in
2018 among males and females due to breast cancer.
The method of cancer treatment is determined based on the cancer type, stage of cancer
development, and the person’s health. The three common cancer treatments are radiation,
surgery, and chemotherapy. Radiation therapy uses high energy waves to makes small breaks in
the DNA inside cancer cells. During this process, abnormal cells are destroyed and new, normal
cells replace the dead ones (Lawrence, Ten Haken & Giaccia, 2008). Surgery is used to remove a
tumor prior to metastasis, whereas chemotherapy uses drugs to inhibit cancer cell function (Ho
Im et al., 2016).
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Cannabinoids
Cannabinoids are compounds originally discovered in the plant Cannabis sativa. They
are potential chemotherapeutic agents being investigated to treat cancer. The discovery of
cannabinoids occurred in the 1940s, and the receptors for these molecules were discovered in the
mid-1980 (Pertwee, 2006). To date, approximately 113 cannabinoids have been isolated from
Cannabis (Namdar et al., 2018).
There are three primary types of cannabinoids: endocannabinoids, synthetic cannabinoids,
and phytocannabinoids (Qamri et al., 2009). Endocannabinoids are endogenous cannabinoids
that the human body synthesizes and releases, which also interact with the CB1 and CB2
receptors. Anandamide is a type of endocannabinoid that binds to CB1 and activates the receptor
(Pertwee, 2008). Synthetic cannabinoids are designed for research purposes, and they also
interact with the CB1 and CB2 receptors (Seely, Lapoint, Moran, & Fattore, 2012). Synthetic
cannabinoids are mildly psychoactive because of their cannabimimetic properties (Grigoryev et
al., 2011).
Phytocannbiniods are cannabinoids that occur naturally in the Cannabis plant; the most
thoroughly investigated phytocannabinoids are THC and CBD (Figure 1) (Borgelt et al., 2013).
CBD has a significantly different action than THC (Gertsch, Pertwee & Di Marzo, 2010). THC
directly activates the CB1 receptor, which causes a change in brain function due to its
psychoactive properties. Unlike THC, CBD has a low affinity for the CB1/CB2 receptors.
However, it causes cellular modulation that leads to an indirect interaction with the CB1 receptor
(Pacher, Batkai, & Kunos, 2006). CBD induces endogenous neurotransmitter uptake, which is
responsible for signal transmission in the brain (Moreira et al., 2011).
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Figure 1. THC and CBD chemical structures.

Cannabinoids serve a purpose in pharmaceutical science, even though Cannabis is just
becoming accepted by society (Gupta, 2014). Due to powerful therapeutic properties used to
treat several medical conditions, cannabinoids have been contributing to pharmaceutical benefits
since 1850. Research has shown that cannabinoids can contribute to factors that help the body
respond to injury, defend against viruses and bacteria, and repair damaged tissues in the body
(Nagarkatti, Pandey, Rieder, Hegde, & Nagarkatti, 2009). Cannabinoids can also regulate energy
in the body by activating the 5-hydroxytryptamine (serotonin) receptor, which contributes to the
reduction of addiction, anxiety, depression, nausea, pain, and vomiting as well as improves
appetite and sleep (Crippa et al., 2010).
CBD and THC inhibit cancer metastasis by activating the CB1 and CB2 receptors (Patsos,
Hicks, Greenhough, Williams, & Paraskeva, 2005). CB1 receptors are in the basal ganglia, brain,
cerebellum, limbic system, and reproductive system. CB2 receptors are correlated with antiinflammatory processes and are, in addition to the locations mentioned, found in the spleen. CB2
is expressed “on demand”, the modulation of CB2 levels is a common feature to cells of
macrophage lineage as they participate in the inflammatory response and undergo differential
gene expression and acquisition of distinctive functional properties (Cabral, 2009).
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Cannabinoids and Cancer
The mechanism by which cannabinoids directly kill breast cancer cells is currently
unknown, but researchers have postulated a potential mechanism. Velasco et al. (2016)
suggested a pathway in which cannabinoids might cause cancer cell apoptosis (Figure 2). THC
stimulates the stress-regulated protein pathway, which enhances the inhibitory interaction of the
pseudokinase homologue 3 with pro-survival kinases, Akt. This leads to inhibition of the
mammalian target of rapamycin complex 1 and the subsequent stimulation of autophagymediated cell death (Velasco et al., 2016).
Velasco et al. ( 2016) proposed the mechanism for glioma cancer cells. Even though the
mechanism of how apoptosis occurs in breast cancer cells is not known, most cancer apoptosis
probably follow a similar mechanism. Researchers have frequently determined that THC and
CBD can kill cancer cells. However, the specific concentration of CBD and THC is rarely
addressed. Sarfaraz et al. (2008) speculated that the concentration makes a difference in whether
there will be apoptosis or proliferation in cancer cells.
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Figure 2. The proposed mechanism of apoptosis caused by cannabinoids on glioma cells
(Velasco et al., 2016).

Sarfaraz et al. (2008) proposed that overexpressed CB1and CB2 receptors may lead to
tumor destruction, but low or no expression of these receptors could lead to cell proliferation and
metastasis because of the suppression of the antitumor immune response. This suggests that
cannabinoids as an anticancer treatment will not exhibit the side effects associated with current
cancer treatments, making cannabinoids a promising contribution to current cancer therapies.
Because the concentration of cannabinoids affects cancer cells, the precise concentration of THC
and CBD needed to cause apoptosis of the breast cancer cells must be examined.
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Methods
This study was conducted at the University of Northern Colorado in the Department of
Chemistry and Biochemistry and the School of Biological Sciences. Cell culture was performed
with a MCF-7 human breast cancer cell line obtained from Bio-Rad (Bio Rad Laboratories,
Hercules, CA, USA). Cultures were kept in an incubator at 37 ºC with 95% humidified air and
5% CO2 . Two controls for this experiment were used: cells in Roswell Park Memorial Institute
(RPMI) culture medium without cannabinoids and cells in the same medium with ethanol. The
ethanol was added to determine the effect ethanol had on cancer cells, due to the fact the drugs
were dissolved in ethanol. Two treatment groups were also used to compare CBD and THC.
These treatment groups were treated with CBD or THC at varying concentrations including 0.1,
1, 10 and 100 micromolar. These concentrations are arbitrarily chosen because there is not an
established baseline of concentrations that might affect the cancer cells. To study whether CBD
and THC cause apoptosis or proliferation in MCF-7 cells, an MTT assay was performed to
determine cell proliferation through a colorimetric measurement of metabolic mitochondrial
activity.
Media
Fresh media was made by adding either a mixture of fetal bovine and horse sera (FBE,
cat. No. VWR) or to a RPMI base. Additionally, penicillin 100 unit/L/streptomycin (100 ug/L
(ThermoFisher, 10378016), sodium pyruvate 1 mM (ThermoFisher, 11360070), bovine insulin
10 mg/mL (ThermoFisher, 12585014), L-glutamine 2 mM (ThermoFisher, 25030081), Hepes
(buffer agent) 10 mM (ThermoFisher, 15630080) and 2-mercaptoethanol 0.142 M
(ThermoFisher, 35602BID) were added to the RMPI to provide a complete media (cRPMI) with
everything the MCF-7 cancer cells need to grow.
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Cell Growth and Passing
After incubation for 24 hours (37 ℃, 95% humidified air, 5% CO2 ), old medium was
discarded and cells were trypsinized by adding 3 mL of trypsin (1x) concentration
(ThermoFisher, 25200-056) to the flask and incubating the flasks at 37 ºC and 5% CO2 for 1-2
min, until cells lifted from the culture flask surface. Six mL of fresh media were added to each
flask to neutralize the trypsin reaction. The cells, now in fresh media, were centrifuged at 1200
rpm in conical tubes for 5 min. Supernatant was discarded, and the cell pellets were re-suspended
in 1 mL of fresh media each. A 10 µL sample of MCF-7 cells was stained with trypan blue (1:1)
and counted using a Countess II Automated Cell Counter. These results were used to determine
the cell density to determine the volume containing the proper number of cells needed to be
grown in each well. The calculated number of the cells were then re-suspended in fresh media
(12 mL in the T-75 flask), then transferred constantly to 96 wells plates and incubated until they
are 80% confluent (roughly 48-64 hr.).
Adding Cannabinoids to the Cancer Cell Cultures
The first control group was suspended in media without any cannabinoids or ethanol (the
vehicle control); the second control group were suspended in media with ethanol equal to the
amount of ethanol in which the cannabinoids were delivered. Each concentration treatment had
three replicates. For the first treatment of breast cancer cells, 0.1 µM CBD was added to each of
the three wells in the first column. The second column had 1 µM of CBD, while the third column
had 10 µM CBD, and lastly the fourth column had 100 µM of CBD. A second set of breast
cancer cells followed the same protocol with the concentrations of THC using a different plate.
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MTT Assay
The plates were incubated (37 ºC, 95% humidified air, 5% CO2 ) for 24 hours.
Tetrazolium dye- MTT assay (ThermoFisher, V13154) was added to the MCF-7 cancer cells
which measures cell metabolic activity to determine the actual percent of the MCF-7 cancer cell
apoptosis (Kowalczewska et al., 2016).
Western Blot
The protocol by Pullen et al. (2012) was used in determining cell viability through
Western blot. MCF-7 cells were analyzed for apoptosis though Western blotting by detecting
PARP cleavage. This allowed comparison of control group apoptosis (baseline) to cells treated
with cannabinoids and served as a preliminary measure of induction of apoptosis, which could be
the basis for later studies examining the timing of apoptosis. MCF-7 cells were treated with lysis
buffer (from Cell Signaling Technology, a detergent containing phosphatase and protease
inhibitors to preserve protein structure) (ThermoFisher, 89900) to obtain intracellular proteins;
immediately after lysis, samples were microcentrifuged for 5 min at 13,000xg. Proteins were
denatured, and chemically reduced at 95-100 ºC in 1X Laemmli buffer containing βmercaptoethanol for 10 min then cooled on ice. The supernatant was subjected to SDS-PAGE
with 4%-20% Tris-glycine polyacrylamide gels for resolution based on size (kDa), and then
electro-transferred to a nitrocellulose membrane. Twenty-five milliliters of 1X Tris-buffered
saline (TBS) were used to wash the nitrocellulose membrane for 5 min at room temperature.
Then, to block unspecific binding, the membrane was incubated at room temperature for 1 h in a
mixture of TBS with 5% (v/v) milk and 0.05% (v/v), (TBST). The membrane was then rinsed
with TBST and incubated with a primary antibody specific for detecting human poly (ADProbosyl) polymerase 1 at 1:1000) diluted in 1X TBST containing 5% bovine serum albumin

15

(BSA), with gentle agitation overnight at 4 °C. The membrane was washed three times for 5 min
each with TBST. The membrane was then incubated for 45 min with anti-rabbit IgG conjugated
to horse radish peroxidase (HRP). TBST was used to wash the membrane and detection was
made by using enhanced chemiluminescence substrate activated by HRP (PerkinElmer, Rodgau,
Germany). Densitometric analysis was performed using ImageJ software (National Institutes of
Health, Bethesda, MD, USA).
Statistical Analysis
An ANOVA was performed to compared cannabinoid concentrations among each other
and with control to determine if there is a significant difference in percent of the breast cancer
cell death in both MTT assay and Western blot. Poc-host test was performed to determine which
effects due to concentrations differ from one another. The treatment groups were compared with
the control, since the control was set as the standard.

Results
The first study (Agyemang, D., & Hyslop, R., in press) determined the exact
concentration of CBD and THC needed to kill MCF-7 breast cancer cells. CBD was more
effective at stimulating apoptosis compared to THC. However, the most effective concentration
of CBD varied between the MTT assay and the Western blot assay. Since the THC was not as
effective as we predicted, we could test the THC in higher concentrations in the future to gauge
effectiveness. Because these are preliminary results, the assays will need to be replicated. This
study will be replicating to determine if the basic findings of the original work are accurate. Due
to the therapeutic potential of CBD and THC, the findings of this study could contribute to the
ever-growing body of knowledge regarding cancer treatments.
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MTT Assay
The MTT assay detects the proliferation of MCF-7 breast cancer cells. As the
proliferation increases, it indicates that the concentration causes stimulation of proliferation in
the MCF-7 breast cancer cells. The lower proliferation indicated that the MCF-7 breast cancer
cells were inhibited by the concentration of the CBD or THC. The media was the control, which
showed typical/expected proliferation of breast cancer cells. As illustrated in Figure 3, CBD is
the more effective inducer of apoptosis of the MCF-7 breast cancer cells compared to the THC
and control. The CBD and THC concentrations at 100 µM were the most effective among the
concentrations.
However, THC concentrations had mixed effects on the MCF-7 breast cancer cells. At 10
µM, THC stimulated the cancer cell growth compared to media alone and that is the opposite
effect hypothesized. Nevertheless, the rest of the THC concentrations had no effect on the
proliferation of the MCF-7 breast cancer cell.
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Figure 3. MCF-7 proliferation as a function of CBD and THC. The first bar of each
concentration is CBD (orange), whereas THC (blue) is the next bar of each concentration.

Western Blot
The Western blot assessment illustrates the ratio between cleaved and uncleaved parp
protein. The ratio is directly proportional to the apoptosis of the MCF-7 breast cancer cells. The
higher ratio of the cleaved to uncleaved PARP protein indicates the apoptosis of the breast
cancer cells with the influence by CBD or THC.
As illustrated in Figure 4, THC concentration caused more apoptosis in MCF-7 breast
cancer cells compared to CBD. However, CBD and THC concentrations at 0.1 µM showed an
increase in the ratio of the cleaved to uncleaved PARP protein indicating that there is an
apoptosis of breast cancer. A decrease in ratio shows no changes in MCF-7 breast cancer cells or
perhaps stimulation occurs, leading to proliferation of the MCF-7 breast cancer cells. As
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illustrated in Figure 4, CBD concentrations of 1 µM and 100 µM showed a decrease in the ratio
which indicates that no apoptosis occurred or perhaps a proliferation of the MCF-7 breast cancer
cells.

CLeavged vs. Uncleaveged
PARP

1.4
1.2
1
0.8
0.6
0.4
0.2
0

media

ethanol

0.1 µM

1 µM

10 µM

100 µM

CBD and THC Concentration
Figure 4. Detection of Parp-protein cleavage. An increase in the bar graph, higher than the
media, indicates MCF-7 breast cancer cell apoptosis. CBD (orange), THC (blue), and the
Controls (green).
Statistical Analysis
ANOVA - MTT Assay
A t-test of CBD or THC to media show no significant different, however comparison of
each concentration to the media differs. The two-way analysis of variance is an extension of the
ANOVA that examines the influence of two different categorical independent variables on one
continuous dependent variable. The use of two-way ANOVA is to understand if there is an
relationship between the two independent variables which in this case, are CBD and THC, on the
dependent variable which in this case is the apoptosis of the MCF-7 breast cancer cells shown in
Figure 5 and 6. The P-values need to be equal to or less than 0.0500 to account for statistical
significant differences between the variables.
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As illustrated in Table 1, the comparison of CBD and THC to media has a P value = 0.0598 which
indicates that there is not any statistical significance, however, there is a significant difference
among each concentration. As illustrated in Table 2, each concentration including the control were
compared with all the concentrations to find a significant difference. All the concentrations show no
significant difference except for the relationship between 10 µM THC and 100 µM CBD, which
stipulate that at 100 µM CBD concentration, the concentration has an opposite effect on the MCF-7
breast cancer cells compared to all the concentrations and the media.
Table 1: MTT Assay Comparison of CBD
and THC Treatment to the Media.
Significant difference is P valve of 0.05

Approximate
Ns
No
9
14.97

2

1

0

9
12

C
0. on
1
t
µM rol
T
1
µM HC
10
T
µM HC
10
T
0
µM HC
0.
T
1
µ M HC
CB
1 D
CB
10 D
C
1 0 BD
0
CB
D

Data summary
Number of
treatments (columns)
Number of subjects
(rows)

0.0597

Optical Density

3

ANOVA
P value
Exact or
approximate P value?
P value summary
Are means signif.
different? (P < 0.05)
Number of groups
Friedman statistic

Fig.5. Visual presentation of the comparison
of CBD and THC to the media.
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Table 2: Multiple Comparison of t-Test of Each Group to Every other Group. The difference is
significant at P-valve ≤ 0.05.

Dunn's multiple comparisons test
Control vs. 0.1 µM THC
Control vs. 1 µM THC
Control vs. 10 µM THC
Control vs. 100 µM THC
Control vs. 0.1 µM CBD
Control vs. 1 CBD
Control vs. 10 CBD
Control vs. 100 CBD
0.1 µM THC vs. 1 µM THC
0.1 µM THC vs. 10 µM THC
0.1 µM THC vs. 100 µM THC
0.1 µM THC vs. 0.1 µM CBD
0.1 µM THC vs. 1 CBD
0.1 µM THC vs. 10 CBD
0.1 µM THC vs. 100 CBD
1 µM THC vs. 10 µM THC
1 µM THC vs. 100 µM THC
1 µM THC vs. 0.1 µM CBD
1 µM THC vs. 1 CBD
1 µM THC vs. 10 CBD
1 µM THC vs. 100 CBD
10 µM THC vs. 100 µM THC
10 µM THC vs. 0.1 µM CBD
10 µM THC vs. 1 CBD
10 µM THC vs. 10 CBD
10 µM THC vs. 100 CBD
100 µM THC vs. 0.1 µM CBD
100 µM THC vs. 1 CBD
100 µM THC vs. 10 CBD
100 µM THC vs. 100 CBD
0.1 µM CBD vs. 1 CBD
0.1 µM CBD vs. 10 CBD
0.1 µM CBD vs. 100 CBD
1 CBD vs. 10 CBD
1 CBD vs. 100 CBD
10 CBD vs. 100 CBD

Significant?
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Yes
No
No
No
No
No
No
No
No
No
No

Adjusted P Value
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
0.1868
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
0.1868
>0.9999
>0.9999
>0.9999
0.0108
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
>0.9999
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ANOVA- Western Blot
As illustrated in Table 3, the comparison of CBD and THC to media is P value = 0.7364
indicates that there is not any statistical significance. In addition, the P valve for all the
concentrations also indicated that there is not any statistically significant difference between all
these concentrations.

Table 3: Western blot comparison of CBD and THC treatment to the media.
Significant difference is when the P valve is 0.05
ANOVA
P value
Exact or approximate P value?
P value summary
Do the medians vary signif. (P < 0.05)?
Number of groups
Kruskal-Wallis statistic
Data summary
Number of treatments (columns)
Number of values (total)

Column2
0.7364
Approximate
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10
6.035
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Figure 6: Comparison of the THC and CBD to the media. B. Multiple comparison, t-test of each
group to every other group.

Discussion
In this study, the ascertainment of various concentrations of CBD and THC that influence
MCF-7 breast cancer apoptosis was the focus. Studies have shown that certain cannabinoids
cause the apoptosis of cancer cells, but only with a certain concentration, which has not been
well documented. Therefore, this study was to determine the exact concentration of CBD and
THC needed to kill MCF-7 breast cancer cells, rather than creating mass multiplication leading
to more growth of the cancer. An MTT assay and Western blot were the methods used to conduct
this experiment. The first study (Agyemang, D., & Hyslop, R., in press) stated that CBD was
more effective at stimulating apoptosis compared to THC. However, the most effective
concentration of CBD varied between the MTT assay and the Western blot assay. The first study
(Agyemang, D., & Hyslop, R., in press) research results were preliminary; however, this research
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is a replication with a larger sample sizes. This is a better representative of the population
making the data more accurate and precise.
As illustrated in the MTT Assay, 100 µM is lower in proliferation in both CBD and THC
which indicated inhibition of the MCF-7 breast cancer cells. The most salient finding is that 100
µM CBD was the most effective concentration when looking at the MTT assay assessment.
However, THC concentration results vary. At concentration of 100 µM, the THC inhibit the
cancer growth, but at 10 µM concentration of THC increase proliferation, meaning the drugs
stimulates a growth in the MCF-7 breast cancer cell. Visually, the MTT assay illustrated that
CBD was more effective overall drug compared to THC, however the t-Test results indicate that
there is not any statistically significant difference. Blasco-Benito et al. (2018) suggested that the
combination of cannabinoids with estrogen receptor- or HER2-targeted therapies (tamoxifen and
lapatinih, respectively) or with cisplatin, produced additive anti-proliferative responses in cell
cultures; THC and CBD did not show any significant different comparing to the control due to
the lack of these combinations. Takeda et al. (2008) concluded that RT-PCR analysis
demonstrated that there was no detectable expression of CB receptors in MCF-7 cells therefore
cannabinoids had no effect on the cells. However, with the presence of CB receptors cause Δ9THC to inhibit the proliferation of MCF-7 cells.
As illustrated in the Western blot assessment, as the CBD concentrations increase, the
apoptosis decreased in MCF-7 breast cancer cells. As illustrated in figure 4, 0.1 µM CBD
concentration resulted in the most apoptosis comparing to all the CBD concentrations. Western
blot results conflict with the MTT Assay; this may be due to fact that there was a larger sample
size in the MTT assay then there was in the western blot. THC concentration had mixed effect on
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the MCF-7 breast cancer cells. As illustrated in figure 4, 0.1 µM concentration was most
effective for both CBD and THC.
However, the most effective concentrations of CBD and THC on the MCF-7 breast
cancer cells as assessed by Western blot are different from MTT assay’s most effective
concentration. Even though Western blot and MTT assay have different values of what
concentration was effective, both methods show that there is indeed an apoptosis of MCF-7
breast cancer cells due to the influence of CBD or THC. However, this effective concentration
was not statistically significant different. Petreocells et al. (1998) research indicated that
anandamide works best on the MCF-7 breast cancer cell with concentrations of 5-10 µM which
works by blocking human breast cancer cell proliferation through CBI-like receptor-mediated
inhibition of endogenous prolactin action at the level of prolactin receptor.
Focusing on the Western blot, THC has the opposite effect at concentrations of 1 µM and
100 µM indicating that there was no apoptosis among MCF-7 breast cancer cell or perhaps
stimulated proliferation. Comparing the information to the MTT assay, 10 µM THC caused
proliferation but for the Western blot it was 1 µM and 100 µM. The proliferation occurred in
both methods proving that THC could perhaps stimulate proliferation instead of inhibitions of
the MCF-7 breast cancer cells. Sarfaraz et al. (2008) stated that low doses of cannabinoids cause
acceleration of proliferation of the cancer cells instead of inducing apoptosis. Sarfarz et al.
results were supported by THC concentration at 10 µM from MTT assay and 1 µM, 100 µM
from Western blot assay.
Statistically, there is no significant difference between CBD and THC from the Western
blot. Furthermore, there is no significant difference among all the concentrations from the
Western blot, but visually there is trend. Even though the statistical data show no significant
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difference between the media and the concentration, multiple reports such as Blasco-Benito et al.
(2018), Sarfaraz et al. (2008), Velasco et al. (2016) and more have shown that cannabinoid do in
fact cause anti-proliferation of cancer cells. The lack of statistically significant difference in this
research could be because the sample sizes were not quite large enough.
THC and CBD appeared to be effective on the MCF-7 cancer cells; 100 µM or 0.1 µM
showed inhibition of MCF-7 cancer cells depending on either Western blot or the MTT assay
was used. Moving forward, an alternative to the MTT assay could be used since MTT assay is
not sensitive enough for the time points examined. Using Western blot to narrow down between
these two concentrations in which the drug causes inhibition of the proliferation of breast cancer
and testing enough to get a statistically significant difference between the concentration of CBD
and THC to media will be the next focus. Favorable findings may provide an accessible and
affordable cannabinoid-based treatment for patients.
Conclusions
CBD and THC appeared to be effective at stimulating apoptosis of the MCF-7 breast
cancer cells, however, there was no statistically significant difference. Western blot illustrated
that at 0.1 µM, CBD and THC are the most effective at stimulating inhibition of the MCF-7
human breast cancer cells, while MTT assay illustrated that at 100 µM, CBD and THC are most
effective at stimulating apoptosis of the MCF-7 breast cancer cells. Since Western blot is the
more reliable method, the concentration provided from the western blot should be the focus,
however, the sample size for the western blot was small. Therefore, a larger sample sizes for the
western blot will be the next focus.
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